Sinotherapeutics (SH:688247) Xin Lang Cai Jing·2025-10-13 01:36Core Insights - Xuantai Pharmaceutical's stock increased by 0.19% on October 10, with a trading volume of 31.76 million yuan [1] - The company reported a financing net purchase of 2.46 million yuan on the same day, with a total financing balance of 107 million yuan, representing 2.19% of its market capitalization [1] - The company’s main business includes the research, production, and sales of generic drugs, as well as CRO services [1] Financing and Trading Data - On October 10, Xuantai Pharmaceutical had a financing buy-in of 8.41 million yuan and a financing repayment of 5.95 million yuan, resulting in a net financing purchase of 2.46 million yuan [1] - The current financing balance of 107 million yuan is above the 90th percentile of the past year, indicating a high level of financing activity [1] - There were no short sales or repayments on the same day, with a short balance of 0.00 shares, also indicating a high level of inactivity in short selling [1] Financial Performance - For the first half of 2025, Xuantai Pharmaceutical achieved a revenue of 220 million yuan, reflecting a year-on-year growth of 0.74% [2] - The net profit attributable to shareholders for the same period was 45.59 million yuan, showing a decline of 15.82% year-on-year [2] Shareholder and Dividend Information - As of June 30, 2025, the number of shareholders decreased by 4.4% to 8,020, while the average circulating shares per person increased by 4.6% to 17,745 shares [2] - The company has distributed a total of 74.36 million yuan in dividends since its A-share listing [3] - Among the top ten circulating shareholders, the China Securities Shanghai State-owned Enterprise ETF increased its holdings by 109,900 shares [3]